RU2498414C1 - Method for dermal flap survival growth in reduced circulation with sildenafil - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: dermal flap is simulated in laboratory animals on the second day of experiment. Sildenafil 2.2 mg/kg is introduced intraperitoneally on the first, third and fifth day of the experiment.

EFFECT: dermal flap survival rate in reduced circulation with no side effects.

1 tbl, 1 ex

Description

The invention relates to medicine, in particular to experimental pharmacology, and can be used to correct ischemia.

Closest to the claimed solution is a method of increasing the survival of a skin flap on a leg by distant ischemic preconditioning, described by M. Pokrovsky. et al. Patent for invention RU 2429547 C1.

However, this decision does not assess the effect of sildenafil on the survival rate of a skin flap under conditions of reduced blood circulation.

The advantage of this method is that the activation of preconditioning mediators - nitric oxide and protein kinases, and the main effector link - ATP-dependent potassium channels is carried out by a pharmacological drug. In addition, it has been proven that sildenafil is free from unwanted side effects in the dose used.

The technical result of the invention is the development of a method for increasing the survival of a skin flap under reduced blood circulation, including the use of sildenafil.

The technical result is achieved by the fact that when modeling a skin flap under reduced blood circulation on the second day of the experiment, sildenafil is injected intraperitoneally to the laboratory animal at a dose of 2.2 mg / kg on the first, third and fifth days of the experiment.

The method is carried out as follows.

The experiments were carried out on white Wistar rats weighing 220-250 g. Modeling of the skin flap was carried out under anesthesia (chloral hydrate 300 mg / kg ip) on the second day of the experiment. Having departed 1 cm from the xiphoid process along the white line of the abdomen, having previously sized the size of the stencil, a skin flap is cut out: 1 cm - base, 4 cm - length, (keeping the feeding vessel) is isolated in a plastic bag, the edges of the skin are sutured with a continuous suture. The assessment of the survival of the skin flap is carried out on the sixth day of the experiment, by measuring the area of the surviving flap tissue in the group of animals with modeling of the skin flap and in the group with modeling of the skin flap and administration of nicorandil.

Sildenafil ("VIAGRA", Pfizer) is administered intragastrically at a dose of 2.2 mg / kg on the first, third and fifth days of the experiment.

When statistical data processing is calculated, the average value, the standard deviation. Differences are considered significant at p <0.05.

EXAMPLE OF SPECIFIC IMPLEMENTATION.

The experiments were carried out on white rats male Wistar strain weighing 220-250 g. The experimental animals were divided into the following groups:

1. control (n = 10);

2. using sildenafil (n = 10).

Animals of both groups had a skin flap modeled on the second day of the experiment. Under anesthesia (chloral hydrate 300 mg / kg intraperitoneally), departing 1 cm from the xiphoid process along the white line of the abdomen, having previously sized the stencil, a skin flap was cut out: 1 cm - base, 4 cm - length (keeping the supply vessel) isolated in a plastic bag, the edges of the skin were sutured with a continuous suture. Animals of the second group were intraperitoneally injected with sildenafil at a dose of 2.2 mg / kg on the first, third and fifth days of the experiment;

Assessment of the survival of the skin flap was performed on the sixth day of the experiment, measuring the area of healthy tissue.

The results of the evaluation of the survival of the skin flap are presented in table 1.

Table 1 Survival indices of a skin flap under conditions of reduced blood circulation on the 5th day after modeling (the 6th day of the experiment) (M ± m). Group (n = 10) Healthy flap tissue area in cm % Modeling of the skin flap (control) 1.6 ± 0.02 40 Modeling skin flap + sildenafil 3.0 ± 0.04 * 75 Note. * - p≤0.05 when compared with the control group; sildenafil intragastrically at a dose of 2.2 mg / kg on the first, third and fifth days of the experiment;

The introduction of experimental animals sildenafil contributed to a significant (p <0.05) increase in the area of surviving flap tissue.

Thus, the obtained results allow one to ascertain an increase in the survival of a skin flap under conditions of reduced blood circulation, simulated on the second day of the experiment, with intraperitoneal administration of sildenafil to the experimental animal at a dose of 2.2 mg / kg on the first, third, and fifth days of the experiment.

Claims (1)

A method of increasing the survival of a skin flap in conditions of reduced blood circulation, characterized in that when modeling a skin flap in conditions of reduced blood circulation on the second day of the experiment, sildenafil is administered to the laboratory animal at a dose of 2.2 mg / kg on the first, third and fifth days of the experiment.